检索结果-南通市图书馆

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery:clinical trials and post-marketing experience

引用

Gastroenterology Report 2019年第5期7卷 322-330,I0001页

作者： Bo Shen Aimee Blake Karen Lasch michael smyth Fatima Bhayat Center for Inflammatory Bowel Disease Digestive Disease and Surgery InstituteCleveland ClinicClevelandOHUSA Global Patient Safety Evaluation Takeda Pharmaceuticals International Co.CambridgeMAUSA US Medical Office Takeda Pharmaceuticals USA Inc.DeerfieldILUSA Global Medical Affairs Takeda Development Centre Europe LtdLondonUK Kyowa Kirin International plc ChertseyUK

Background:Patients with inflammatory bowel diseases frequently require surgery,but immunotherapies used in disease management may increase the risk of post-operative *** investigated frequencies of post-operative complications in patients who received vedolizumab—a gut-selective antibody approved for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease—in clinical-trial and post-marketing ***:This post hoc analysis of safety data from GEMINI 1,GEMINI 2,and long-term safety studies included patients who had had colectomy or bowel surgery/*** from the post-marketing Vedolizumab Global Safety Database were also analysed(data cutoff point:19 May 2016).Adverse events relating to post-operative complications were identified using Medical Dictionary for Regulatory Activities preferred ***:Of 58 total surgeries in patients included in GEMINI 1 and GEMINI 2,post-operative complications were reported for 3/51 vedolizumab-treated patients(5.9%)and 1/7 placebo-treated patients(14.3%).In the long-term safety study,157/2,243 patients(7%)had colectomy or bowel surgery/resection;of these 157 patients who underwent surgery,11(7%)experienced a post-operative *** time between last pre-operative vedolizumab dose and surgery was 23 days in GEMINI 1,20 days in GEMINI 2,and 39–40 days in the long-termsafety *** the post-marketing setting,based on data covering approximately 46,978 patient-years of vedolizumab exposure,post-operative complications were reported in 19 ***:In clinical trials,complications of colectomy and bowel surgery/resection appeared infrequent,with minimal difference between vedolizumab and *** frequency of post-operative complications in the post-marketing setting appears low.

关键词： inflammatory bowel disease colorectal surgery vedolizumab

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

不确定性院前预警评分可否用来早期识别需要紧急治疗的疑似脓毒症患者?

引用

英国医学杂志中文版 2022年第1期25卷 46-51页

作者： Steve Goodacre Ben Thomas michael smyth Jon M Dickson 刘雯丽(译) 梁志欣(校) School of Health and Related Research(ScHARR) University of SheffieldSheffield S14DAUK Warwick Medical School University of WarwickCoventry CV47ALUK Faculty of Medicine Dentistry and Health University of SheffieldSheffield S102HQUK 解放军总医院第一医学中心呼吸与危重症医学科

脓毒症的早期识别和治疗对降低死亡率至关重要,但这只有当疑似脓毒症患者在紧急救护系统中接受优先治疗的情况下才能实现。一种可以识别这些患者的推荐方法是使用早期预警评分。这些评分使用简单的临床测量来计算指示不良结局风险,并且... 详细信息

脓毒症的早期识别和治疗对降低死亡率至关重要,但这只有当疑似脓毒症患者在紧急救护系统中接受优先治疗的情况下才能实现。一种可以识别这些患者的推荐方法是使用早期预警评分。这些评分使用简单的临床测量来计算指示不良结局风险,并且一些指南对其在脓毒症早期识别中的应用提出了建议(框图1)。

关键词：脓毒症患者早期识别紧急救护早期预警评分不良结局临床测量院前不确定性

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Platelet-rich plasma increases transforming growth factor-beta1 expression at graft-host interface following autologous osteochondral transplantation in a rabbit model

引用

World Journal of Orthopedics 2015年第11期6卷 961-969页

作者： Lorraine A Boakye Keir A Ross John M Pinski Niall A smyth Amgad M Haleem Charles P Hannon Lisa A Fortier John G Kennedy Department of Orthopaedic Surgery Hospital for Special Surgery Department of Orthopaedic Surgery Rush University Medical Center Department of Clinical Sciences Cornell University College of Veterinary Medicine

AIM: To explore the effect of platelet-rich plasma on protein expression patterns of transforming growth factor-beta1(TGF-β1) in cartilage following autologous osteochondral transplantation(AOT) in a rabbit knee cartilage defect ***: Twelve New Zealand white rabbits received bilateral AOT. In each rabbit, one knee was randomized to receive an autologous platelet rich plasma(PRP) injection and the contralateral knee received saline injection. Rabbits were euthanized at 3, 6 and 12 wk post-operatively. Articular cartilage sections were stained with TGF-β1 antibody. Histological regions of interest(ROI)(left, right and center of the autologous grafts interfaces) were evaluated using Meta Morph. Percentage of chondrocytes positive for TGF-β1 was then ***: Percentage of chondrocytes positive for TGF-β1 was higher in PRP treated knees for selected ROIs(left; P = 0.03, center; P = 0.05) compared to control and was also higher in the PRP group at each post-operative time point(P = 6.6 × 10^(-4), 3.1 × 10^(-4) and 7.3 × 10^(-3) for 3, 6 and 12 wk, respectively). TGF-β1 expression was higher in chondrocytes of PRP-treated knees(36% ± 29% vs 15% ± 18%)(P = 1.8 × 10^(-6)) overall for each post-operative time point and ROI. CONCLUSION: Articular cartilage of rabbits treated with AOT and PRP exhibit increased TGF-β1 expression compared to those treated with AOT and saline. Our findings suggest that adjunctive PRP may increase TGF-β1 expression, which may play a role in the chondrogenic effect of PRP in vivo.

关键词： Platelet rich plasma Transforming growth factor-beta Autologous osteochondral transplantation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Res:HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果

引用

现代生物医学进展 2017年第18期17卷 I0001-I0002页

作者： Mikolaj Medon Eva Vidacs Stephin J Vervoort Jason Li Misty R. Jenkins Kelly M. Ramsbottom Joseph A. Trapani Mark J. smyth Phillip K. Darcy Peter W. Atadja michael A. Henderson Ricky W. Johnstone Nicole M. Haynes Cancer Therapeutics Program Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre (VCCC) Melbourne Victoria Australia.Division of Surgical Oncology Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia. Cancer Therapeutics Program Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre (VCCC) Melbourne Victoria Australia. Cancer Therapeutics Program Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre (VCCC) Melbourne Victoria Australia. Bioinformatics Consulting Core Facility Cancer Research Division Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia. Cancer Immunology Research Program Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia.Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia. Cancer Immunology Research Program Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia. Cancer Immunology Research Program Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia.Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia. Immunology in Cancer and Infection Laboratory QIMR Berghofer Medical Research Institute Herston Queensland Australia. Cancer Immunology Research Program Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia.Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia. China Novartis Institute for Biomedical Research Shanghai China. Division of Surgical Oncology Peter MacCallum Cancer Centre VCCC Melbourne Victoria Australia. Cancer Therapeutics Program Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre (VCCC) Melbourne Victoria Australia.Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia. Cancer Therapeutics Program Peter MacCallum Cancer Centre Victorian Comprehensive Cancer Centre (VCCC) Melbourne Victoria Australi

最近来自澳大利亚墨尔本的研究人员发现组蛋白去乙酰化酶抑制剂可以发动宿主免疫作为其抗肿瘤效应的一个基础。该研究为增强一些肿瘤免疫治疗药物的杀伤作用提供了新的方向。在这项发表在国际学术期刊Cancer Research上的研究中，研究... 详细信息

最近来自澳大利亚墨尔本的研究人员发现组蛋白去乙酰化酶抑制剂可以发动宿主免疫作为其抗肿瘤效应的一个基础。该研究为增强一些肿瘤免疫治疗药物的杀伤作用提供了新的方向。在这项发表在国际学术期刊Cancer Research上的研究中，研究人员发现组蛋白去乙酰化酶抑制剂panobinostat可以通过宿主免疫增强trastuzumab这种单抗治疗药物的抗肿瘤效果。

关键词：组蛋白去乙酰化酶抑制剂抗肿瘤效应治疗药物治疗效果 HDAC 单抗 Res 阳性

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

骨转移所致骨相关事件的处理

引用

英国医学杂志中文版 2009年第2期12卷 101-105页

作者： Anna N Wilkinson Raymond Viola michael D Brundage 梅齐(译) 于世英(校) Department of Oneology Ottawa Hospital Cancer Centre 503 Smyth Road Ottawa ON Canada KIH 1C4 Palliative Care Medicine Program Department of Medicine Queen' s University 34 Barrie Street Kingston ON Canada K7L 3J7 Division of Cancer Cave and Epidemiology Queen's Cancer Beseareh Institute Kingston ON Cansda KTL 3N6 武汉华中科技大学同济医学院附属同济医院肿瘤中心

疼痛是姑息治疗中需控制的最常见症状，而超过一半的癌症转移患者罹患骨转移相关的疼痛。约80％的骨转移来源于乳腺癌、肺癌和前列腺癌。转移性乳腺癌和前列腺癌患者生存时间较长，因而控制骨痛对他们尤为重要。因为初级保健医生与患者... 详细信息

疼痛是姑息治疗中需控制的最常见症状，而超过一半的癌症转移患者罹患骨转移相关的疼痛。约80％的骨转移来源于乳腺癌、肺癌和前列腺癌。转移性乳腺癌和前列腺癌患者生存时间较长，因而控制骨痛对他们尤为重要。因为初级保健医生与患者及家属长期密切的联系，他们是实施姑息治疗适合的人选，并能使各方都满意。

关键词：骨转移相关事件前列腺癌患者转移性乳腺癌初级保健医生姑息治疗常见症状癌症转移

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：